About C4Diagnostics
C4Diagnostics is a Healthcare company based in Marseille (France) founded in 2017 by Sam Dukan, Younes Lazrak, and Emilie Fugier. C4Diagnostics has raised $1.75 million across 2 funding rounds from investors including Bpifrance, Angels Sante and Turenne Groupe. Its chief executive is Sam Dukan. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified. Its competitors include Inflammatix, MeMed, GenMark Diagnostics, Sunbird Bio and T2 Biosystems and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Provider of technology for detection and count of microorganisms. The technology helps in the detection of ultra-specific (L. pneumophila), semi-specific (Gram - vs. Gram ), and generic (all microorganisms, including eukaryotes). The technology helps to trigger the metabolic pathways of microorganisms by introducing a synthetic sugar with bio-orthogonal function to their membrane. The company focuses on Legionnaires disease diagnosis and urinary tract infections (UTI) screening.
- Headquarters Marseille, France
- Founders Sam Dukan, Younes Lazrak, Emilie Fugier
- SectorsHealthcare
- Email••••••••
- Website c4diagnostics.com
- Social LinkedIn X
- Total Equity Funding$1.75M (USD)
in 2 rounds
- Latest Funding Round$363.04K (USD), Debt – Conventional
Feb 2019
- InvestorsBpifrance
& 4 more
Funding Insights of C4Diagnostics
C4Diagnostics has successfully raised a total of $1.75M across 2 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $363.04 thousand completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.75M
- Total Rounds 2
- Last Round Debt – Conventional — $363,044
- First Round $1.75M
(Sep 2018)
- Investors Count 5
All 2 funding rounds of C4Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2019 | $363,044 | Debt – Conventional | – | – | |
| Sep 2018 | $1.75M | Seed | – | Turenne Groupe, Smalt Capital | – |
5 investors in total: 5 institutional.
Investors in C4Diagnostics
C4Diagnostics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Bpifrance, Angels Sante and Turenne Groupe.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are made in companies across diverse sectors. | – | turennecapital.com | Paris, France | |
Smalt Capital is engaged in capital investment and renewable energy financing. | 2000 | smaltcapital.com | Marseille, France | |
Paris-based healthcare startups are funded by an angel network. | 2010 | angelssante.fr | Paris, France | |
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France | |
Invests in and supports French startups with high growth potential. | 2008 | am-businessangels.org | Paris, France |
Investor details for C4Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of C4Diagnostics
10 people are tracked at C4Diagnostics (5 in leadership, 5 in board & advisors).
| Name | Role | Group |
|---|---|---|
Sam Dukan | Co-Founder & Co-CEO | Leadership |
Younes Lazrak | Co-Founder & Co-CEO | Leadership |
Emilie Fugier | Co-Founder | Leadership |
Dhikra Feki | Head of Quality, Regulatory Affairs & Market Access | Leadership |
Guillaume Tournier | Head of Finance & Accounting | Leadership |
Pierre Chavagne | Board Member | Board & advisors |
Andrei Polukhtin | Board Member | Board & advisors |
Armand Perrin | Board Member | Board & advisors |
Sandra Dubos | Board Member | Board & advisors |
Marguerite Pappalardo | Board Member | Board & advisors |
Complete people profiles for C4Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of C4Diagnostics
3 dated milestones of C4Diagnostics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded C4Diagnostics is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Debt – Conventional, of $363K.
Competitors of C4Diagnostics
C4Diagnostics has 10 listed competitors in our database, 9 of them funded. They include Inflammatix, MeMed, GenMark Diagnostics, Sunbird Bio and T2 Biosystems, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| me-med.com | 2009 | Tirat Carmel, Israel | $163M | – | Provider of machine learning based diagnostic solutions for infectious diseases | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| sunbirdbio.com | 2020 | Singapore | $14M | – | Diagnostic technologies for infectious, cancer, and neurological diseases are developed. | |
| t2biosystems.com | 2006 | Lexington, United States | $454.3M | 166 | Miniaturized MRI platforms for clinical diagnostics are developed. | |
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| molbiodiagnostics.com | 2000 | Salcete, India | $123.98M | 714 | Point-of-care molecular platforms for infectious disease detection are developed. | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. | |
| kryptosbio.com | 2017 | Hayward, United States | $12.7M | – | Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology. | |
| seegene.com | 2000 | Seoul, South Korea | – | – | Developer of molecular diagnostic kits to detect infectious and genetic diseases |
Detailed competitors of C4Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as C4Diagnostics (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about C4diagnostics
Complete news archive for C4Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about C4Diagnostics
C4Diagnostics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
C4Diagnostics is headquartered in Marseille, France. It is registered at Marseille, Provence-alpes-cote D'azur, France.
Sam Dukan is the current CEO of C4Diagnostics. They have also founded this company.
C4Diagnostics is a funded company, having raised a total of $1.75M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.75M, raised on Sep 2018.
Provider of technology for detection and count of microorganisms. The technology helps in the detection of ultra-specific (L. pneumophila), semi-specific (Gram - vs. Gram ), and generic (all microorganisms, including eukaryotes). The technology helps to trigger the metabolic pathways of microorganisms by introducing a synthetic sugar with bio-orthogonal function to their membrane. The company focuses on Legionnaires disease diagnosis and urinary tract infections (UTI) screening.
C4Diagnostics's top competitors include Visby Medical, Inflammatix and MeMed.
C4Diagnostics has 5 investors. Key investors include Bpifrance, Angels Sante, Turenne Groupe, Smalt Capital, and Arts and Crafts Business Angels.